PRECLINICAL DEVELOPMENT OF THE PI3K ALPHA SELECTIVE AND PIK3CA MUTANT SELECTIVE INHIBITOR GDC-0077 AND PREDICTION OF ITS HUMAN PHARMACOKINETICS

被引：0

作者：

Pang, Jodie ^{[1
]}

Baumgardner, Matthew ^{[1
]}

Braun, Marie-Gabrielle ^{[1
]}

Cheong, Jonathan ^{[1
]}

Edgar, Kyle ^{[1
]}

Friedman, Lori ^{[1
]}

Hanan, Emily ^{[1
]}

Jaochico, Allan ^{[1
]}

Ma, Shuguang ^{[1
]}

Plise, Emile ^{[1
]}

Schmidt, Stephen ^{[1
]}

Liu, Ning ^{[1
]}

Song, Kyung ^{[1
]}

Staben, Steve ^{[1
]}

Salphati, Laurent ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

来源：

DRUG METABOLISM AND PHARMACOKINETICS | 2019年 / 34卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

P56

引用

页码：S37 / S37

页数：1

共 50 条

[1] GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models
Edgar, Kyle
Hong, Rebecca
Song, Kyung
Schmidt, Steven
Hafner, Marc
Arrazate, Alfonso
Williams, Erin
De La Cruz, Cecile
Oeh, Jason
Sampath, Deepak
Staben, Steve
Friedman, Lori
[J]. CANCER RESEARCH, 2020, 80 (04)
[2] Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
Hanan, Emily J.
Braun, Marie-Gabrielle
Heald, Robert A.
MacLeod, Calum
Chan, Connie
Clausen, Saundra
Edgar, Kyle A.
Eigenbrot, Charles
Elliott, Richard
Endres, Nicholas
Friedman, Lori S.
Gogol, Emily
Gu, Xiao-Hui
Thibodeau, Rebecca Hong
Jackson, Philip S.
Kiefer, James R.
Knight, Jamie D.
Nannini, Michelle
Narukulla, Raman
Pace, Amanda
Pang, Jodie
Purkey, Hans E.
Salphati, Laurent
Sampath, Deepak
Schmidt, Stephen
Sideris, Steve
Song, Kyung
Sujatha-Bhaskar, Swathi
Ultsch, Mark
Wallweber, Heidi
Xin, Jianfeng
Yeap, SiewKuen
Young, Amy
Zhong, Yu
Staben, Steven T.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (24) : 16589 - 16621
[3] Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development
Edgar, Kyle
Hanan, Emily
Staben, Steven
Schmidt, Stephen
Hong, Rebecca
Song, Kyung
Young, Amy
Hamilton, Patricia
Arrazate, Alfonso
de la Cruz, Cecile
Belvin, Marcia
Nannini, Michelle
Friedman, Lori S.
Sampath, Deepak
[J]. CANCER RESEARCH, 2017, 77
[4] Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Kα that promotes selective loss of mutant-p110α
Staben, Steven T.
[J]. CANCER RESEARCH, 2017, 77
[5] Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-p110 alpha protein
Braun, Marie-Gabrielle
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
[6] GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies
Hong, Rebecca
Edgar, Kyle
Song, Kyung
Steven, Schmidt
Young, Amy
Hamilton, Patricia
Arrazate, Alfonso
De La Cruz, Cecile
Chan, Connie
Pang, Jodie
Salphati, Laurent
Belvin, Marcia
Nannini, Michelle
Staben, Steven
Friedman, Lori
Sampath, Deepak
[J]. CANCER RESEARCH, 2018, 78 (04)
[7] A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors
Juric, Dejan
Kalinsky, Kevin
Oliveira, Mafalda
Cervantes, Andres
Bedard, Philippe
Krop, Ian
Hamilton, Erika
Schmid, Peter
Varga, Andrea
Turner, Nick
Italiano, Antoine
Saura, Cristina
Gambardella, Valentina
Veitch, Zachary
Dickmann, Leslie
Kotani, Naoki
Fredrickson, Jill
Kapp, Amy
Hutchinson, Katie
Royer-Joo, Stephanie
Vaze, Anjali
Schutzman, Jennifer
Jhaveri, Komal
[J]. CANCER RESEARCH, 2020, 80 (04)
[8] Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-p110 alpha protein
Braun, Marie-Gabrielle
Chan, Connie
Clausen, Saundra
Edgar, Kyle
Eigenbrot, Charles
Eliott, Richard
Endres, Nick
Friedman, Lori
Gerland, Keira
Gu, Xiao-Hu
Hamilton, Pat
Han, Chong
Hanan, Emily
Hong, Rebecca
Jackson, Philip
Kelly, Sean
Knight, Jamie
Lee, Man-Ling
Lu, Aijun
MacLeod, Calum
McKenzie, Aija
Nannini, Michelle
Narukulla, Raman
Nguyen, Amanda
Pang, Jodie
Purkey, Hans
Salphati, Laurent
Sampath, Deepak
Schmidt, Stephen
Schutt, Leah
Heald, Robert
Song, Kyung
Ultsch, Mark
Xin, Jianfeng
Yeap, Kuen
Young, Amy
Zhong, Zoe
Staben, Steven
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[9] Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human
Salphati, Laurent
Pang, Jodie
Plise, Emile G.
Chou, Bilin
Halladay, Jason S.
Olivero, Alan G.
Rudewicz, Patrick J.
Tian, Qingping
Wong, Susan
Zhang, Xiaolin
[J]. XENOBIOTICA, 2011, 41 (12) : 1088 - 1099
[10] Determination of the PI3Kα selective inhibitor alpelisib mechanism of action and efficacy in ER+/ PIK3CA mutant breast cancer preclinical models
Fritsch, Christine
Pfister, Estelle
Ebel, Nicolas
Guthy, Daniel
Schnell, Christian
Hofmann, Francesco
[J]. CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →